Elevated cyclin E level in human clear cell renal cell carcinoma: possible causes and consequences

• Autorzy: Nauman A. , Turowska O. , Poplawski P. , Master A. , Tanski Z. , Puzianowska-Kuznicka M.
• Języki publikacji: EN

Abstrakty

EN

The expression of cyclin E gene (CCNE) in relation to the expression of its major regulatory protein, E2F1, was examined in clear cell renal cell carcinomas (ccRCC). We show that the overexpression of E2F1 is accompanied by the significant increase of the mean amounts of cyclin E mRNA, as well as of total cyclin E protein and its low molecular weight forms in cancer tissues as compared to peritumoral controls. A significant increase of the mean amount of total cyclin E was found in peritumoral tissues compared to cancer-free kidneys, suggesting that cancer cells might secrete factors having a profound influence on the metabolism of neighbouring tissues. A significant, positive correlations between E2F1 protein and total cyclin E mRNA, as well as between E2F1 protein and full length cyclin E protein were found in cancer-free kidneys and in peritumoral tissues, but not in ccRCCs. The overexpression of cyclin E positively correlated with the decreasing degree of tumor differentiation, implicating a role for cyclin E in the promotion of tumorigenesis.

Słowa kluczowe

EN

human disease; cyclin E promoter; cyclin E level; man; clear cell renal cell carcinoma; gene expression; regulatory protein; cancer; cyclin E gene

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2007
• Tom: 54
• Numer: 3
• Opis fizyczny: p.595-602,fig.,ref.

Twórcy

autor

Nauman A.

• Medical Center of Postgraduate Education, Marymoncka 99, 01-813 Warsaw, Poland

autor

Turowska O.

autor

Poplawski P.

autor

Master A.

autor

Tanski Z.

autor

Puzianowska-Kuznicka M.

Bibliografia

• Akli S, Keyomarsi K (2003) Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol Ther 2: S38–S47.
• An J, Rettig MB (2005) Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. Mol Cell Biol 25: 7546–7556.
• Bales E, Mills L, Milam N, McGahren-Murray M, Bandyopadhyay D, Chen D, Reed JA, Timchenko N, van den Oord JJ, Bar-Eli M, Keyomarsi K, Medrano EE (2005) The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res 65: 692–697.
• Bedrosian I, Lu KH, Verschraegen C, Keyomarsi K (2004) Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene 23: 2648–2657.
• Cobrinik D, Whyte P, Peeper DS, Jacks T, Weinberg RA (1993) Cell cycle-specific association of E2F with the p130 E1A-binding protein. Genes Dev 7: 2392–2404.
• Cohen HT, McGovern FJ (2005) Renal cell carcinoma. N Engl J Med 353: 2477–2490.
• Donnellan R, Chetty R (1999) Cyclin E in human cancers. FASEB J 13: 773–780.
• Evan GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411: 342–348.
• Fang ZH, Han ZC (2006) The transcription factor E2F: a crucial switch in the control of homeostasis and tumorigenesis. Histol Histopathol 21: 403–413.
• Geng Y, Eaton EN, Picon M, Roberts JM, Lundberg AS, Gifford A, Sardet C, Weinberg RA (1996) Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene 12: 1173–1180.
• Haitel A, Wiener HG, Neudert B, Marberger M, Susani M (2001) Expression of the cell cycle proteins p21, p27, and pRb in clear cell renal cell carcinoma and their prognostic significance. Urology 58: 477–481.
• Hwang HC, Clurman BE (2005) Cyclin E in normal and neoplastic cell cycles. Oncogene 24: 2776–2786.
• Jackson PK, Chevalier S, Philippe M, Kirschner MW (1995) Early events in DNA replication require cyclin E and are blocked by p21CIP1. J Cell Biol 130: 755–769.
• Kamiya Y, Puzianowska-Kuznicka M, McPhie P, Nauman J, Cheng SY, Nauman A (2002) Expression of mutant thyroid hormone nuclear receptors is associated with human renal clear cell carcinoma. Carcinogenesis 23: 25–33.
• Madej A, Puzianowska-Kuznicka M, Tanski Z, Nauman J, Nauman A (2003) Witamin D receptor binding to DNA is altered without the change in its expression in human renal clear cell cancer. Nephron Exp Nephrol 93e: e150–e157.
• Mazumder S, DuPree EL, Almasan A (2004) A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapy. Curr Cancer Drug Targets 4: 65–75.
• Moroy T, Geisen C (2004) Cyclin E. Int J Biochem Cell Biol 36: 1424–1439.
• Muller H, Bracken AP, Vernell R, Moroni MC, Christians F, Grassilli E, Prosperini E, Vigo E, Oliner JD, Helin K (2001) E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev 15: 267–285.
• Muller-Tidow C, Metzger R, Kugler K, Diederichs S, Idos G, Thomas M, Dockhorn-Dworniczak B, Schneider PM, Koeffler HP, Berdel WE, Serve H (2001) Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage nonsmall cell lung cancer. Cancer Res 61: 647–653.
• Ohtani K, DeGregori J, Nevins JR (1995) Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci USA 92: 12146–12150.
• Pajalunga D, Crescenzi M (2004) Regulation of cyclin E protein levels through E2F-mediated inhibition of degradation. Cell Cycle 3: 1572–1578.
• Polanowska J, Fabbrizio E, Le Cam L, Trouche D, Emiliani S, Herrera R, Sardet C (2001) The periodic down regulation of cyclin E gene expression from exit of mitosis to end of G1 is controlled by a deacetylase- and E2Fassociated bipartite repressor element. Oncogene 20: 4115–4127.
• Porter DC, Keyomarsi K (2000) Novel splice variants of cyclin E with altered substrate specificity. Nucleic Acids Res 28: E101
• Porter DC, Zhang N, DanesC, McGahren MJ, Harwell RM, Faruki S, Keyomarsi K (2001) Tumor specific proteolytic processing of cyclin E generates hyperactive lowermolecular-weight forms. Mol Cell Biol 21: 6254–6269.
• Puzianowska-Kuznicka M, Nauman A, Madej A, Tanski Z, Cheng S, Nauman J (2000) Expression of thyroid hormone receptors is disturbed in human renal clear cell carcinoma. Cancer Lett 155: 145–152.
• Puzianowska-Kuznicka M, Pietrzak M, Turowska O, Nauman A (2006) Thyroid hormones and their receptors in the regulation of cell proliferation. Acta Biochim Polon 53: 641–650.
• Schraml P, Bucher C, Bissig H, Nocito A, Haas P, Wilber K, Seelig S, Kononen J, Mihatsch MJ, Dirnhofer S, Sauter G (2003) Cyclin E overexpression and amplification in human tumours. J Pathol 200: 375–382.
• Spruck CH, Won KA, Reed SI (1999) Deregulated cyclin E induces chromosome instability. Nature 401: 297–300.
• Tsantoulis PK, Gorgoulis VG (2005) Involvement of E2F transcription factor family in cancer. Eur J Cancer 41: 2403–2414.
• Weintraub SJ, Chow KNB, Luo RX, Zhang SH, He S, Dean DC (1995) Mechanism of active transcriptional repression by the retinoblastoma protein. Nature 375: 812–815.